Finance

Lists
Why is NWBO up 6,08%?
Dive Deeper
NWBO:OTCMKTS
Northwest Biotherapeutics Inc
USD 0,16
+6,08%
(+0,0090) 1D
USD 0,16
+1,85% (+0,0029)
After hours
Closed: 9 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NWBO...
Open
USD 0,16
High
USD 0,16
Low
USD 0,15
Mkt. cap
267,79 m
Avg. vol.
3,46 m
Volume
19,06 m
52-wk high
USD 0,34
52-wk low
USD 0,14
EPS
-USD 0,03
Beta
-0,62
Shares outstanding
1,71 mjd
No. of employees
105
Open
USD 0,16
High
USD 0,16
Low
USD 0,15
Mkt. cap
267,79 m
Avg. vol.
3,46 m
Volume
19,06 m
52-wk high
USD 0,34
52-wk low
USD 0,14
EPS
-USD 0,03
Beta
-0,62
Shares outstanding
1,71 mjd
No. of employees
105
News stories
From web sources and news partners
Profile
Northwest Biotherapeutics, Inc. is a development-stage American pharmaceutical company headquartered in Maryland that focuses on developing immunotherapies against different types of cancer. It was founded in 1996 by Alton L. Boynton. Wikipedia
About Northwest Biotherapeutics Inc
CEO-
Employees105
Founded01 Jan. 1998
Headquarters-
Sector-
Websitenwbio.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
200,00 k
672,00 k
494,00 k
807,00 k
Cost of goods sold
7,45 m
5,55 m
4,86 m
5,70 m
Cost of revenue
7,45 m
5,55 m
4,86 m
5,70 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,07 m
8,62 m
6,54 m
6,71 m
Operating expense
7,07 m
8,62 m
6,54 m
6,71 m
Total operating expenses
14,52 m
14,18 m
11,39 m
12,41 m
Operating income
-14,32 m
-13,50 m
-10,90 m
-11,60 m
Other non operating income
-3,45 m
1,14 m
9,53 m
64,00 k
EBT including unusual items
-26,83 m
851,00 k
-3,07 m
-9,22 m
EBT excluding unusual items
-21,20 m
-14,82 m
-5,06 m
-13,47 m
Income tax expense
-
-537,00 k
-
-
Effective tax rate
-
-63,10%
-
-
Other operating expenses
-
-
-
-
Net income
-26,83 m
1,39 m
-3,07 m
-9,22 m
Net profit margin
-13 414,50%
206,55%
-621,25%
-1 142,63%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-2,62 m
-2,65 m
-2,35 m
-1,81 m
Net interest expenses
-2,62 m
-2,65 m
-2,35 m
-1,81 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-13,87 m
-12,78 m
-10,13 m
-10,83 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme